|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investorideas.com, a global news source and investor resource covering cannabis stocks issues a sector news alert on Canadian cannabis stocks following the Senate’s recent passing of Bill C-45 to federally legalize cannabis. In a recent Deloitte report, A society in transition, an industry ready to bloom, “Canadians are expected to spend as much as $7.17 billion on cannabis products in 2019 and increase their overall consumption by up to 35 per cent once recreational cannabis is legalized later this year, according to a new report by Deloitte. “Uruguay and Canada are leading the way on adult-use legalization, and Germany broke barriers in 2017 on medical-use availability.
In the afterglow of Canada's recent legalization of recreational cannabis, news is coming out about some thought-provoking and eyebrow-raising partnerships between mainstream consumer products and cannabis producers. This emerging trend could portend good things for EVITRADE Health Systems Corp. (quoted in Canada on the Canadian Securities Exchange as CSE:EVA and quoted in the United States on the OTC Markets as OTCQB: AXHLF) as it looks to explore new avenues and expand revenue channels.
VANCOUVER, BC / ACCESSWIRE / June 22, 2018 / EVITRADE Health Systems Corp. (OTCQB: AXHLF, CSE: EVA,) (the "Company") announces that it has signed a Letter of Intent to collaborate with West Coast Medical Solutions Ltd. ("WCMS"). WCMS together with their partner Ecovita Packaging Ltd. ("Ecovita") intend to undertake a project to apply to become a Licensed Dealer (LD) as issued by Health Canada for Class A precursors. The Company will focus on uses regarding medical cannabis, tetrahydrocannabinol ("THC") and cannabidiol (CBD).
EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: AXHLF) (the “Company”) announces that it has signed the Definitive Agreement with Cantech Molecular Research Inc. (“Cantech”). Among the many progressive capabilities EVA will gain with the Cantech acquisition is the ability to produce true homozygotic plants with a highly select and consistent set of traits.
EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: AXHLF) (the “Company”) announces that it has embarked on a program to utilize its contacts in the blockchain technology space to marry the security of blockchain technology with the Company’s interest in the international industrial Hemp trade. The Company has signed a Letter of Intent with Veri-Medical Systems (“VeriMed” or the “Company”) to potentially acquire the Company which is involved in developing a blockchain based “seed-to-sale” protocol focussed on enhancing the integrity of the sale of Hemp based products such as cannabidiol (“CBD”). “We are very excited to be standing at the cross-road of being able to combine the security that block-chain technologies offer with the bright future of Hemp based protocols and products” said C.K., CEO for Evitrade Health.